WO2023194924 - PROCESS FOR PREPARATION OF RELUGOLIX
National phase entry:
Publication Number
WO/2023/194924
Publication Date
12.10.2023
International Application No.
PCT/IB2023/053463
International Filing Date
05.04.2023
Title **
[English]
PROCESS FOR PREPARATION OF RELUGOLIX
[French]
PROCÉDÉ DE PRÉPARATION DE RÉLUGOLIX
Applicants **
GLENMARK LIFE SCIENCES LIMITED
Inventors
PALLE, Venkata Raghavendra Charyulu
KADAM, Suresh
SINHA, Sukumar
GAVHANE, Sachin
BHADANE, Shailendra Nilkanth
CHAUDHAR, Uddhav Popat
MINDHE, Ajit Shankar
RANE, Namrata Govind
SHELKE, Nikhil Uttam
Priority Data
202221021078
08.04.2022
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP India
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2667 | |
| EPO | Filing, Examination, Granting | 20031 | |
| Japan | Filing, Examination, Granting | 2672 | |
| South Korea | Filing, Examination, Granting | 3061 | |
| USA | Filing, Examination, Granting | 6740 |
Total:
35,171
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention is related to a process for the preparation of relugolix, a compound of formula I, also known as N- [4-[1-[(2,6-difluoro phenyl) methyl]-5-[(dimethyl amino]- methyl]-3-(6-methoxy-3-pyridazinyl]-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d] pyrimidin-6-yl] phenyl]-N'-methoxyurea, or a pharmaceutically acceptable salt thereof. The present invention is also related to a process for the preparation of crystalline relugolix.[French]
La présente invention concerne un procédé de préparation de rélugolix, un composé de formule I, également connu sous le nom de N-[4-[1-[(2,6-difluorophényl)méthyl]-5-[(diméthyl amino]-méthyl]-3-(6-méthoxy-3-pyridazinyl]-2,4-dioxo-1,2,3,4-tétrahydro-thiéno[2,3-d]pyrimidin-6-yl] phényl]-N'-méthoxyurée, ou un sel pharmaceutiquement acceptable de celui-ci. La présente invention concerne également un procédé de préparation de rélugolix cristallin.